Welcome to our dedicated page for Modular Med news (Ticker: MODD), a resource for investors and traders seeking the latest updates and insights on Modular Med stock.
Modular Medical, Inc. reports developments tied to its diabetes-focused medical device business and its Pivot tubeless insulin patch pump. The company is a development-stage insulin delivery technology company using patented technologies to support insulin pump adoption among people with diabetes. Pivot is described as a two-part tubeless patch pump with a removable 3 mL reservoir, disposable battery, and smartphone connectivity for bolus and monitoring.
Recurring MODD news includes FDA 510(k) clearance for Pivot, manufacturing validation, commercial-readiness updates, investor presentations, Nasdaq listing compliance, reverse stock split actions, shareholder voting matters, capital-structure disclosures, governance updates, and operating and financial results.
Modular Medical (MODD) announced a contract with a national U.S. pharmacy benefit manager (PBM), making its Pivot™ tubeless patch pump insulin delivery system available through that PBM.
The company views this agreement, which it says is with one of the largest PBMs in the country, as a key commercialization milestone that can broaden patient access and support validation of Pivot as an accessible diabetes therapy option. PBMs manage prescription drug benefits and formulary placement for health plans and employers, helping reduce barriers to access and streamline reimbursement. Pivot is a wearable, three-day tubeless patch pump designed to transition patients from multiple daily injections to continuous insulin infusion.
Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot tubeless insulin patch pump system, expanding functionality ahead of its planned fourth quarter 2026 commercial launch.
The clearance covers upgrades that provide greater flexibility and customization in bolus dosing, an enhanced user interface, and other software improvements. The company said these are the first in a series of planned enhancements to the Pivot platform, including the ability to customize the amount of insulin delivered with each button press. Pivot is designed as a simple, wearable insulin delivery system providing continuous basal and bolus insulin over a three-day wear period, with the aim of offering an accessible alternative to multiple daily injections for a broader diabetes population.
Modular Medical (MODD) announced that CEO Jeb Besser will present at Tribe Public's CEO Presentation and Q&A webinar titled "The Road To Revenue: Modular Medical's Strategy For Launching Pivot" on Friday, September 4, 2026 at 8:30 a.m. Pacific / 11:30 a.m. Eastern.
The complimentary event is hosted by Tribe Public's Managing Member, John F. Heerdink, Jr., who will relay participant questions to management. Interested attendees can register at PivotLaunch.TribePublic.com, after which they may submit questions in advance via email to research@tribepublic.com or during the session through the Zoom chat feature.
The webinar will focus on Modular Medical's Pivot™ tubeless patch pump, a simple, wearable insulin delivery platform designed for continuous subcutaneous insulin infusion with basal and bolus delivery over a three-day wear period. The system is intended to provide an accessible pathway from multiple daily injections to insulin pump therapy for insulin-dependent adults, addressing what the company describes as a multi-billion-dollar market opportunity.
Modular Medical (NASDAQ: MODD) will participate in the Association of Diabetes Care & Education Specialists 2026 Annual Conference in Columbus, Ohio, from August 7-10, 2026. Management will host booth #1516 to showcase live demonstrations of its Pivot™ tubeless insulin patch pump ahead of an October launch in five U.S. markets.
Modular Medical (NASDAQ: MODD) announced it will begin the first phase of full commercial launch of its Pivot™ tubeless patch insulin pump in October 2026, targeting five U.S. markets: Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia. This initial rollout is described as a capital-efficient step focused on regions with high insulin pump prescribing activity and large populations of patients using multiple daily injections (MDI), Pivot’s primary target group.
According to the company, these markets account for 14% of the nation’s highest-volume insulin pump prescribers, 15% of all new insulin pump starts, and 21% of prescribers with high affinity for new brand adoption for MDI patients, based on PurpleLab® data for the 24 months ended June 2025. Modular Medical has also partnered with Inizio, a global healthcare commercialization firm, to provide commercial execution, provider engagement, and launch support aimed at accelerating awareness and adoption of the Pivot pump in initial and future markets.
Modular Medical (NASDAQ:MODD) announced the formation of the Pivot Innovation Council, a cross-functional group of clinicians and healthcare experts created to guide clinical and commercial strategy for its Pivot™ tubeless patch pump. Diabetes care leader Robert Gabbay, MD, PhD, FACP has been appointed chairman.
The council will advise on target patient populations, workflow integration, evidence-generation initiatives, and the Pivot product roadmap and go-to-market approach. According to Modular Medical, Dr. Gabbay’s extensive background in diabetes care transformation, population health, and patient-centered care will support efforts to expand clinical evidence, strengthen provider engagement, and improve access to simpler insulin pump therapy.
Modular Medical (NASDAQ: MODD) announced a pilot collaboration with IMO Health to build a terminology-powered phenotypic algorithm that identifies diabetes patients who may benefit from Pivot tubeless patch insulin pump therapy directly within electronic health records (EHRs).
The project targets multiple‑daily‑injection patients showing pump hesitancy, prior pump failure, or suboptimal outcomes, using clinician‑guided phenotypes mapped to IMO Health’s validated terminology value sets. Modular Medical plans to pilot the solution at a large‑scale diabetes center and create a scalable framework supporting its expected fourth quarter commercial launch of the Pivot pump.
Modular Medical (NASDAQ: MODD) reported results from an independent market research study on its FDA-cleared Pivot tubeless patch pump. The research found positive payor receptivity driven by Pivot’s differentiated, simple modular design, tubeless and reusable architecture, 300 IU reservoir, and one-button operation.
According to Modular Medical, payors viewed Pivot favorably for potential reimbursement through pharmacy benefit channels, citing alignment of its disposable component structure and anticipated contracting strategy with existing frameworks. Respondents also indicated interest in strategic partnership models with large healthcare organizations to support broader patient access, evidence generation, and long-term adoption of simplified insulin delivery solutions.
Modular Medical (NASDAQ: MODD) reported results from a diabetes patient research initiative indicating strong demand for simpler insulin pump therapy among multiple daily injection users. In a 100-person assessment, 97% said they would consider pump therapy and were open to alternative treatment options.
The company highlighted unmet needs, including frequent hospitalizations related to severe glycemic events and difficulties finding private places to inject insulin. Modular Medical targets an estimated 4.5 million U.S. patients using both basal and mealtime insulin as the primary market for its Pivot tubeless insulin patch pump and has engaged Thrivable to conduct further research with 20 engaged patients and a 300-person survey.
Modular Medical (NASDAQ:MODD) announced submission to the FDA of software enhancements for its Pivot tubeless insulin patch pump. The update covers increased patient customization, UI improvements and other upgrades. According to Modular Medical, this is the first in a planned series of Pivot platform enhancements, following clearance and market launch of the core form factor.